Analysis of associations between spleen stiffness and esophageal-gastric varices in patients with HBV- related liver cirrhosis receiving anti-viral treatment
10.3969/j.issn.1006-5725.2015.07.006
- VernacularTitle:脾脏硬度与接受抗病毒治疗乙肝肝硬化患者食管胃底静脉曲张的关系
- Author:
Haiyan SHI
;
Min XU
;
Haohui DENG
;
Keng CHEN
;
Hongbo GAO
;
Shumei ZHANG
;
Baolin LIAO
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
HBV-related liver cirrhosis;
Esophageal-gastric varices;
Liver stiffness;
Spleen stiffness
- From:
The Journal of Practical Medicine
2015;(7):1057-1060
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the diagnosis value of spleen stiffness measurement by transient elastography (FibroScan, FS) for esophageal-gastric varices (EV) in patients with HBV-related liver cirrhosis receiving anti-viral treatment. Method Total of 41 patients from Jan 2014 to Dec 2014 diagnosed with HBV-related liver cirrhosis receiving anti-viral treatment were enrolled. All patients were evaluated for spleen and liver stiffness measurement by FS and checked by gastroscopy for diagnosis of EV. Using gastroscopy as the gold standard, the area under receiver operating characteristic curve (AUROC) were used to evaluate the value of the spleen stiffness and liver stiffness in diagnosis of EV and its degree. Results The spleen and liver FS values in patients were (40.64 ± 25.45) kPa and (20.76 ± 13.21) kPa respectively, and they showed a positive correlation (r = 0.402, P < 0.001). The spleen FS values in patients without EV were significantly lower than those in patients with mild EV and moderate-severe EV (all P < 0.05). Furthermore, they showed significantly lower in patients with mild EV than those in patients with moderate-severe EV too (P < 0.05). The AUROC of spleen FS in patients with EV was 0.863, with sensitivity of 79.4% and specificity of 83.2%. Moreover, the AUROC of spleen FS in patients with moderate-severe EV was 0.924, with sensitivity of 87.9% and specificity of 91.3%. Both of them were much higher than those of liver FS. Conclusion Spleen FS may act as a non-invasive marker to predict EV and its degree in patients with HBV-related liver cirrhosis receiving anti-viral treatment.
